Current and future treatment strategies for iron overload cardiomyopathy.
Iron overload cardiomyopathy is the major cause of death in transfusion-dependent thalassemia (TDT) patients. Growing evidence demonstrates that combined iron chelators, or the combination of an iron chelator with antioxidant(s) are effective in diminishing myocardial iron deposition and attenuating cardiac dysfunction. This review comprehensively summarizes basic and clinical reports on the therapeutic efficacy of combined iron chelators, or the combination of an iron chelator with antioxidant(s) on the heart. Promising benefits of these treatments in preventing cardiac dysfunction due to iron overload could provide extensive insight into future therapeutic strategies for better treatment and prevention of cardiomyopathy in TDT patients.
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand.
Suwakon
S
Wongjaikam
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand.
Sirinart
S
Kumfu
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai, Thailand.
Siriporn C
SC
Chattipakorn
Thalassemia Research Center, Institute of Molecular Bioscience, Mahidol University, Nakhon Pathom, Thailand.
Suthat
S
Fucharoen
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand. Electronic address: nchattip@gmail.com.
Nipon
N
Chattipakorn
D000818:Animals; D009202:Cardiomyopathies / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism
D002317:Cardiovascular Agents; D007502:Iron Chelating Agents
Antioxidant; Deferasirox; Deferiprone; Deferoxamine; Iron chelator; Iron overload cardiomyopathy